, Singapore

Daily Markets Briefing: STI down 0.6%

Index poised for a technical rebound.

OCBC Investment Research said:

The rebound by the US indices overnight is likely to cue the local bourse to a more optimistic opening this morning.

After sliding another 0.6% yesterday, the STI could be poised for a technical rebound soon. Despite this, we note that any rebound from here could potentially invite investors to sell into strength again thereafter.

For now, we pegged the immediate resistance at the 3300 psychological obstacle, with the next resistance at the 3320 support-turned-resistance.

On the downside, we now see the immediate base at the 3270 minor trough, followed by the next support at the 3240 key resistance-turned-support.

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

AI growth stalls as 78% cite weak data infrastructure
Confluent said firms are prioritising data streaming as they move AI projects from pilots into production.
Singapore emerges as key hub in Asia-Pacific’s next medtech wave
The city-state’s regulatory strength helps translate medical innovations into globally validated products.
Healthcare